Bronstein, Gewirtz & Grossman LLC Urges Aardvark Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Aardvark Therapeutics (NASDAQ: AARD) is facing a newly filed class action lawsuit alleging violations of federal securities laws tied to its Feb. 13, 2025 IPO and trading between Feb. 13, 2025 and May 14, 2026. The suit seeks unspecified damages on behalf of investors who acquired shares during the class period. This is a negative legal development that could increase perceived risk around the company’s disclosures and reporting.

Analysis

This is less a litigation story than a cost-of-capital story. For a small, cash-burning therapeutics name, class-action headlines mainly matter because they can deter follow-on investors, complicate any secondary raise, and increase the discount rate applied to future pipeline value. The immediate price reaction is often bigger than the eventual economic damage, but the overhang can persist for months if management has to defend disclosures while still funding the business.

The second-order losers are other recent life-science IPOs with thin balance sheets and no near-term commercial revenue: the market tends to reprice the whole cohort when one issuer is attacked, especially if underwriting quality or disclosure discipline comes into question. If AARD needs capital within the next 2-4 quarters, the lawsuit increases the chance that any raise clears at a wider discount and with more warrants, which is where real dilution risk enters. That effect is much more important than the legal merits themselves.

Contrarian view: these cases often resolve as nuisance settlements unless there is a clean accounting or clinical-data issue, so the headline may be overdone if the stock has already de-rated materially. The key falsifier is whether the company can avoid a financing event over the next 6-12 months and maintain operating runway without revising guidance or disclosing adverse trial/commercial data. If there is no imminent capital need, the trade is probably better expressed as a volatility event than a structural short.

Key Decisions for Investors

• Do not force a standalone short in AARD unless borrow is easy and liquidity is sufficient; most of the value risk here is financing-driven, not legal-damages-driven, so the cleaner catalyst is any pre-announced capital raise over the next 1-3 months.
• If options are liquid, use a small AARD put spread into any relief rally rather than chasing the initial headline move; target a 2-3x payoff if the stock revisits the post-headline low or the company flags a capital need.
• Pair trade: short AARD against long XBI on any sector-wide weakness. The thesis is idiosyncratic cost-of-capital compression in AARD, while XBI provides beta neutralization if broader biotech sentiment stabilizes.
• Set a financing alert: if cash runway implies less than 12 months, the thesis turns more bearish; if runway is comfortably beyond 12-18 months and no disclosure issues emerge, cover into the next pop because the legal overhang may fade faster than expected.
• Watch for underwriter or auditor reactions in the next earnings/8-K cycle; any delay, restatement, or amended disclosure would be the real negative catalyst and would justify increasing downside exposure.